SLC6A3 and Parkinson disease: The impairment of dopamine (DA) neurons, inhibition of tyrosine hydroxylase (TH), lower striatal dopamine transporter (DAT) availability in substantia nigra (SN), the accumulation of Lewy bodies arise from α-Syn accumulation, and the activation of A1 neurotoxic astrocytes are pathological features of PD [117,130,131,132].